Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RNA with free AI briefings, catalyst countdowns, and dilution alerts.

RNA · Atrium Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$293.6M Cash, Pro Forma
60.1mo Cash Runway
Follow RNA by email Get an email when RNA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RNA, unsubscribe in one click. Privacy

📣 What RNA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ropivacaine HCL Renal Carcinoma Phase 3 · NCT07092566 Recruiting
Clonidine HCL Renal Carcinoma Phase 3 · NCT07092566 Recruiting
Ketorolac Renal Carcinoma Phase 3 · NCT07092566 Recruiting
Vaccine Pediatric Cancer Phase 2 · NCT04948619 Recruiting
Arylsulfatase A Germ Cell Tumor Phase 2 · NCT06866964 Recruiting
Cisplatin Lung Cancer Stage II Phase 2 · NCT03141359 Active not recruiting
ATR 1072 Cardiac Glycogenosis Phase 1/2 · NCT07738107 Recruiting
Nexatoclax (LP-118) Philadelphia Positive Acute Lymphoblastic Leukemia Phase 1 · NCT07614022 Recruiting

Also used in these trials (approved or third-party drugs, not RNA's own candidates): Epinephrine, Bupivacaine, Anastrozole, Palbociclib, Paclitaxel, Olutasidenib, Nivolumab, Metformin Hydrochloride, Etoposide, Elotuzumab, Durvalumab, Carboplatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RNA had $232.1M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $293.6M pro forma, before operating spending after that date:

It burns about $14.6M/quarter from operations, an estimated runway of 60.1 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RNA files for a raise →

👥 Who Owns RNA

Insiders 2.4% Institutions (210 holders) 67.2% Public and other holders 30.4%
HolderTypeShares% of sharesAs of
Sessa Capital IM, L.P. Institution (13G, 5%+) 1,500,000 6.95% 2026-06-30
T. Rowe Price Associates, Inc. Institution (13G, 5%+) 1,472,984 6.83% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 1,135,757 5.27% 2026-06-30
Sarah Boyce
Director · +20,000 options
Insider 138,668 0.64% 2026-09-18
Kathleen P. Gallagher
Chief Executive Officer and President, D · +205,000 options
Insider 119,729 0.56% 2026-09-18
Steven George Hughes
Chief Medical Officer · +60,000 options
Insider 51,638 0.24% 2026-09-18
Husam Younis
Chief Scientific Officer · +60,000 options
Insider 41,441 0.19% 2026-09-18
Rocio Martin Hoyos
Chief Strategy Officer · +60,000 options
Insider 38,340 0.18% 2026-09-18
Brendan R. Winslow
Chief Financial Officer · +60,000 options
Insider 36,859 0.17% 2026-09-18
Stephanie Kenney
Chief Corporate Affairs Officer · +60,000 options
Insider 33,085 0.15% 2026-09-18
W. Michael Flanagan
Director · +20,000 options
Insider 31,974 0.15% 2026-09-18
Troy Edward Wilson
Director · +20,000 options
Insider 11,731 0.05% 2026-02-26

Share count 21,571,507 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RNA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RNA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.